Nasdaq To Suspend KaloBios Pharma On Jan 13

(RTTNews) - The Nasdaq Stock Market announced that KaloBios Pharmaceuticals, Inc. (KBIO) will be suspended from Nasdaq effective January 13, 2016.

Trading in the Company's securities has been halted since December 17, 2015. The trading halt will no longer be in effect upon the suspension of KaloBios from Nasdaq, which would allow the Company's securities to be eligible for trading in the over-the-counter markets under the symbol "KBIOQ."

A hearing is scheduled for February 25, 2016, to review the company's appeal of Nasdaq's December 18, 2015 delist determination.